The validity of androgen assays by Carruthers, Malcolm et al.
The validity of androgen assays
MALCOLM CARRUTHERS
1, TOM R. TRINICK
2, & MICHAEL J. WHEELER
3
1Centre for Men’s Health, London,
2Department of Chemical Pathology, The Ulster Hospital, Belfast, and
3Department of
Chemical Pathology, St. Thomas’ Hospital, London, UK
(Received 2 February 2007; accepted 25 May 2007)
Abstract
Problems in the measurement of androgens and in interpreting results have been reviewed and classiﬁed as follows:
Preanalytical factors. The exact sampling conditions in relation to circadian and seasonal variations, diet, alcohol, physical
activity and posture.
Physiological and medical factors. Androgen levels vary according to the patient’s general health, stress, sexual activity and
smoking habits.
Analytical variables. Sample preservation and storage variables are often unknown.
The different androgen assays used have widely differing accuracy and precision and are subject to large inter-laboratory
variation, which especially in women and children can render the results of routinely available direct immunoassays
meaningless.
Interpretation of results. Laboratory reference ranges vary widely, largely independent of methodology, and fail to take into
account the log-normal distribution of androgen values, causing errors in clinical diagnosis and treatment. Other unknowns
are antagonists such as SHBG, estrogens, catecholamines, cortisol, and anti-androgens. As well as age, androgen receptor
polymorphisms play a major role in regulating androgen levels and resistance to their action.
Conclusions. Though laboratory assays can support a diagnosis of androgen deﬁciency in men, they should not be used to
exclude it. It is suggested that there needs to be greater reliance on the history and clinical features, together with careful
evaluation of the symptomatology, and where necessary a therapeutic trial of androgen treatment given.
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Introduction
Androgen deﬁciency has been implicated as an
important contributory factor in coronary heart
disease [1], metabolic syndrome and diabetes in
men [2], desire disorders in women [3], and mental
[4] and physical [5] aging in both sexes. It is of
increasing clinical importance, therefore, to assess the
validity of androgen assays and their interpretation
[6]. This will be considered sequentially from taking a
sample and analysing it, to interpreting the result.
Pre-analytical factors
Circadian variation
About 50–60% of the total testosterone (TT) is
bound strongly to sex hormone binding globulin
(SHBG). A further 40–50% is weakly bound to
albumin, which together with the 1–3% free testos-
terone (FT) makes up the so-called ‘bioavailable’
testosterone (BT). Therefore, the combination of
increased testosterone synthesis at night, with
decreases in its binding proteins due to the
haemodilution of recumbency, causes more marked
circadian variation in BT (57%) and FT (68%) than
in TT (45%) [7]. The reduction in circadian
variation in TT and physical activity with ageing
may however reduce this effect.
Seasonal variations
Circannual variations of 19% in TT and 31% in FT
were described by Svartberg et al. [8], who found
lowest levels in summer, with a peak in the autumn,
with similar but variable results reported in other
studies according to geographic location.
Diet
One of the important variables, which is often not
reported in studies of reference populations and
patients to establish androgen deﬁciency, is whether
samples have been taken in the fasting state, or after
low or high glycaemic meals, both of which might
fall within attempts to deﬁne them as ‘a light
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DOI: 10.1080/13685530701483738breakfast’ [9]. It has been known since 1973 that
testosterone levels in normal males can fall in
response to oral glucose by over 30%, depending
on age, time and glucose load [10]. Recently it has
been found that a standard 75 g oral glucose load in
younger men resulted in a 15% reduction of fasting
TT levels after 30 minutes, which continued for up
to 3 hours [11]. This was shown to be due to an
increase in glucagon-like peptide-1 (GLP-1) redu-
cing the pulsatile release of testosterone, and that the
effect was independent of changes in LH.
The most important long-term nutritional effects
appear to be mainly on SHBG, which is decreased by
high protein, high fat diets such as Atkins, and
increased by vegetarian and high ﬁbre diets [6].
These changes may be largely via insulin levels,
which tend to be lower in vegetarians, and are
inversely related to SHBG. Also, high levels of free
fatty acids interfere with the binding of sex steroids to
SHBG, which can affect the level of FT [12].
Alcohol
Alcohol in low doses has been shown to raise
testosterone levels by 19% in men [13] and women
[14]. Conversely, acute alcohol intoxication, espe-
cially if accompanied by strenuous exercise, can
reduce testosterone levels for up to 22 hours by 23%
[15]. Long-term excess alcohol can cause irreversible
damage both the Leydig and Sertoli cells in the
testes, contribute to obesity, raise oestrogen levels,
and cause sustained androgen deﬁciency.
Physical activity
Besides changes due to haemoconcentration, de-
pending on age and the ﬁtness of the individual,
various intensities of different forms of exercise can
cause wide variations in androgen levels [16]. This
can result in the paradox of young endurance athletes
having subnormal TT and FT [17].
Physiological and medical factors
Illness
Reduced androgen levels have been reported in
serious illnesses, ranging from severe trauma, and
coronary heart disease to liver disease, though it is
always difﬁcult to establish which came ﬁrst. The
MMAS study showed that as a group the 18%
apparently healthy men in their follow-up study had
TT levels 15% above the rest of the 1,156 men
remaining out of the original group of 1,709 [18].
Stress
Both excessive and unpleasant physical and mental
stress can activate the hypothalamo-pituitary-adrenal
axis and reduce either the amount or activity of
androgens. Christiansen in 2004 [16] reviewed the
effects of various types of stress on testosterone
secretion that included a variety of mental and
physical stressors.
Sexual activity
Serum and salivary free testosterone have been
shown to increase in both men and women
with a wide variety of sexual activity, including
masturbation [16].
Smoking
Smokers have been found to have both total and free
testosterone levels 5–15% higher than non-smokers
[19]. Increases in both TT (9%) and SHBG (8%)
were found by Field et al. [20], while DHT increased
14%. The immediate effects of nicotine do not
appear to have been studied, and so it is unclear what
the effect of smoking on the morning of the test
might be.
Analytical variables
Type of sample, separation and storage
Recent studies have shown that samples for
testosterone measurement should be separated
within 6 hours at room temperature, or can be
stored at plus 48C for up to 48 hours before
separation [21]. When frozen at minus 208C, they
are stable for up to three months, and for over six
months at minus 708C. In some epidemiological
studies, these limits have been carried to extremes,
and samples re-analysed after periods up to 10 years
[18], though changes in methodology gave results
over 80% higher for TT and therefore FT in the
later analyses, making the stability of the samples
uncertain. Certainly, it is inadvisable to repeatedly
thaw and freeze samples, as proteins such as SHBG
are likely to denature, giving different results for BT
and CFT.
Although the use of a serum or plasma sample was
acceptable for extraction assays of testosterone, they
are not both valid for use in direct assays. For
example the Bayer Centaur assay is validated for
serum only, as is the Immulite Analyzer. With the
latter values for TT obtained with heparinized
plasma are reported as 10% lower [22] and SHBG
3–6% lower [12]. EDTA and citrated plasma
samples give grossly different results for all direct
assays and should never be used.
Plastic blood collection tubes are now used
extensively and have been compared with glass
collection tubes in which clot retraction is more
rapid and complete. Direct comparison however has
shown no signiﬁcant difference in testosterone levels
between samples collected in glass and plastic
tubes [23].
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cause a positive bias in TT estimations, up to þ28%
for two of the methods in common use [24]. The
same NHS Medical Devices Agency (MDA) Alert
reported biases on FSH of 743%, total T3 of þ58%,
total T4 of þ34%, and B12 and folate up to þ84%.
The immediate and impractical action required of
the laboratories receiving the alert was to ‘consider
advising clinicians who have commissioned these
tests on the need to recall or retest patients whose test
results may have been affected’.
However in a later study [25] of 15 immunoassays
performed on Bayer Advia Centaur using blood
specimens collected into four different BD Vacutai-
ner tubes (plain, old and newly released BD SSTII
Advance, and BD PSTII), the plain tubes and old
SSTII Advance tube results showed no bias for
testosterone, CA15-3, follicle-stimulating hormone
and folate assays, but gave a positive bias for cortisol
and a negative bias for vitamin B12.
Compared with plain tubes, BD PSTII tubes gave
no signiﬁcant bias for thyroid function tests, prolac-
tin, parathyroid hormone, and CA125, but gave a
negative bias for steroid assays, and a positive bias for
gonadotrophins. The results obtained using new BD
SSTII Advance tubes were generally comparable
with those of plain tubes, but only for cortisol did this
study support the bias described by the MDA. They
conclude that BD PSTII tubes should not be used
for steroid hormone measurements on the Bayer
Advia Centaur instrument.
Methodology
Commercial direct automated assays have mostly
replaced the old extraction assays conferring
advantages of ease of analysis, speed and through-
put. However there has been severe criticism of the
analytical accuracy of assays in the measurement of
testosterone in female serum [26]. The functional
sensitivity of the older extraction assays was
0.1 nmol/L (3 ng/dl) whilst direct assays are un-
reliable below 1.0 nmol/L (30 ng/dl) [21]. In
addition some commercial assays show intra-assay
imprecision in female sera ranging from 8.9–21.3%
whilst the ﬁgure for males was an acceptable 3.3–
5.5% [27]. Variations in accuracy between testos-
terone methods and a GCMS standard have been
shown to be up to 218% in America [28] and 96%
in Australia [9]. Even between laboratories using
the same methods, and between batches of reagents
within American laboratories, these are up to 23%,
and only 60% of TT levels within the adult male
range were within 20% of target quality control
values [28].
Within laboratory coefﬁcient of variation, espe-
cially at low levels of testosterone and SHBG can be
as high as 16% [22] and 10% respectively, errors
which are compounded in the calculation of BT
and FT.
Another recent paper lends further support to the
view that immunoassay is unsatisfactory for measur-
ing the testosterone concentrations typically found in
women and children, and that bench-top tandem
mass spectrometers are a desirable alternative tech-
nology for in such cases for measurements in the
clinical laboratory despite the additional cost [29].
This study used stable-isotope dilution liquid
chromatography-tandem mass spectrometry (ID/LC-
MS/MS)tomeasure testosterone in plasmaand serum.
Intra- and interassay imprecision was 515% in the
range 0.3–49 nmol/L. Recovery of testosterone added
to samples at concentrations of 0.625–20 nmol/L was
96% (CV¼12%; n¼26). Correlation with isotope-
dilution gas chromatography-mass spectrometry for 20
pools of clinical samples (range, 0.5–38.5 nmol/L) was
0.99. Various steroids added to double charcoal-
stripped serum showed no interference at the retention
timeof the testosteronepeak.Itwas concluded that ID/
LC-MS/MS has improved accuracy compared with
immunoassay and the low sample volume and simpli-
city, rapidity, and robustness of the method make it
suitable for use as a high-throughput assay in routine
clinical biochemistry laboratories.
Similarly, a reference measurement procedure has
also been described to measure FT using isotope
dilution mass spectrometry following ultraﬁltra-
tion [30]. The method gave maximum within-day,
between-day, and total CVs of 3.0%, 3.1%, and 4.3%,
and satisfactory correlation with indirect equilibrium
dialysis and symmetric dialysis. However, they also
demonstrated that ‘a degree of discordance remains,
which may require a decision from an authoritative
organization on the recommended procedure to
measure free hormone concentrations’.
More recently this group has reported the compar-
ison of four routine analog assays for serum free
testosterone, and the calculated free testosterone
(CFT) with the previous reference measurement
procedure [31]. While the CFT was in good
agreement with the reference method there were
substantial differences in analytical quality of the
analog FT assays. The results suggested that after
extending the validation with a larger variety of
samples, recalibration of some analog assays might be
worth further investigation.
A recent study of the accuracy of 10 immunoassay
methods compared with the reference isotope dilu-
tion gas chromatography-mass spectrometry method
(ID/GC-MS) showed that mean immunoassay re-
sults in women were 46% higher than ID/GC-MS
whilst the mean results in men were 12% lower [32].
The authors concluded, along with many others, that
‘None of the immunoassays tested was sufﬁciently
reliable for the investigation of sera from children and
women, in whom very low, e.g. 0.17 nmol/L (5 ng/
dl), and low, e.g. 51.7 nmol/L (50 ng/dl), testoster-
one concentrations are expected’.
Recent data from UKNEQAS showed that whilst
mean recovery was 99.6% in male serum, the mean
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immunoassay methods [33]. The concentration of
SHBG has been shown to signiﬁcantly affect the
testosterone result and agreement between methods
[27].
The association constant of SHBG, on which
the calculation of BT and CFT depends, has been
reported by various authors as being between 0.6 and
1.9610
9 l/mol [12]. Changing from higher to lower
values of this constant can increase calculated BT by
123% and FT by 254%.
Many of the above problems are well summarized
in a recent position statement by the Endocrine
Society reviewing evidence from published sources,
the College of American Pathologists, and the
clinical and laboratory experiences of the ﬁve very
experienced authors [34]. They emphasize that the
TT concentrations in blood vary over three orders of
magnitude depending on age, gender and the
presence of disease, and that other steroids of similar
structure and abundance in the circulation lead to
assay interference. There is a lack of age and gender-
related normal ranges using standardized assays, and
little agreement on whether TT or the small amount
of FT is the most useful clinical measure.
Following a detailed review of methods for
measuring TT and FT, listing strengths and short-
comings of each, and discussion of the problems and
clinical utility of testosterone measurement in the
different ages and sexes, they give suggested normal
ranges only for adult males. Their authoritative
conclusion is that ‘This review demonstrates that
the manner in which most assays for TT and FT are
currently performed is decidedly unsatisfactory’.
Interpretation of results
Reference ranges
A key study emphasizing how the choice of a
reference range for assays can totally alter the
diagnostic criteria for androgen deﬁciency was a
review of the ranges used in 25 laboratories in
Eastern America [35]. Twelve were leading academic
laboratories, 12 community medical laboratories and
one a national laboratory, the largest in the USA. All
of the academic labs, and eight of the community
centres performed TT measurement, using eight
different methods between them. FT estimations
were performed by six of the academic labs, but only
one of the community labs, using four different
methods, with SHBG being available in ﬁve, but BT
and CFT were only quoted in two of these. FT by
equilibrium dialysis was only offered by the national
laboratory ‘only upon special request’.
Of the 25 labs, there were 17 and 13 different sets
of reference values for TT and FT respectively.
Apparently independent of methodology, the low
reference value for TT ranged from 130 to 450 ng/
dL (4.5–15.6 nmol/L – 350% difference), and the
upper from 486 to 1,593 ng/dL (16.9–55.3 nmol/L –
325% difference). For FT the lower values varied
between 5.0–13.5 pg/ml (174–468 pmol/L – 270%
difference) and the upper 19–54.7 pg/ml (660–
1,896 pmol/L–290% difference).
No laboratory performed independent valuation of
the manufacturer’s reference values, which were
based on standard Gaussian distribution analysis of
largely unpublished data, using 2.5% and 97.5% cut-
off points regardless of any clinical correlation.
As this article points out, if up to a third of men
over the age of 50 are clinically androgen deﬁcient,
as suggested by for example by Heinemann’s Aging
Male Symptoms scale [36], then using these widely
varyingreferencerangesobtainedwithdifferentmeth-
odologies, and an inappropriate statistical model, will
exclude a large majority of men who might beneﬁt
from testosterone treatment. This is made more
confusing by the age-related normal ranges reported
by four of the 12 academic centres for TT, and seven
of the total for FT.
Of the small proportion who are treated, with an
inappropriately low upper range, ‘clinicians may
become unnecessarily concerned that therapeutic
doses of testosterone treatment are excessive if TT
or FT results are higher than reference values’.
Given the choice, 92% of lab directors indicated
that clinically relevant threshold values would be
preferable to current reference values, but would
look to national panels or speciality societies for
these. How such authorities could allow for different
clinical indices of suspicion and laboratory meth-
odologies is unclear.
This article concludes that ‘these results indicate
that the current use of testosterone reference values is
confusing and inadequate. There is a clear need for
standardization and more clinically relevant refer-
ence values to guide clinicians in the diagnosis and
treatment of hypogonadism.’
Age
The data from the Massachusetts Male Aging Study
(MMAS) of 1,709 men aged 40–70 has conﬁrmed
the longitudinal trend for TT to decrease by 1.6%,
BT by 2.5%, and FT by 2.8% per annum, the greater
fall in the latter being due to rising SHBG levels.
Over the 30 year age range studied, this amounts to a
drop of 48% in TT, 75% in BT, and 84% in FT.
This raises the question of whether lower levels of
these fractions found in older men should be
accepted as ‘normal’, and go untreated, even if
associated with symptoms of androgen deﬁciency
and its related disorders.
Log-normal distribution of hormones
Observations in ‘normal subjects’ have shown that
androgen values are log-normally distributed [37],
usually revealed by the fact that the distribution
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most hormones.
In spite of this, ‘improper statistics’ [38] have
continued to be used to characterize the normal
range of biochemical and endocrine measurements.
Application of log transformation
to ‘reference ranges’
Population studies have consistently shown that
testosterone data is skewed and that log transformation
of the data should be performed [9,18]. A signiﬁcantly
different picture of conditions associated with
androgen deﬁciency in the adult male is likely to result
from this simple but important statistical change.
The differences in the range of androgen values
given by the arithmetic and logarithmic distributions
can totally alter reference ranges. For example, a
study of the distribution of androgens in patients with
symptoms of androgen deﬁciency [6] showed that on
average, the logarithmic transformed means are 9%
lower than the arithmetic means, and the lower and
upper limits of the logarithmic distribution increased
by 30% of the arithmetic means. Applying these log
conversion values to the study of 249 ‘healthy’ men
by Vermeulen [39] gives the results seen in Figure 1.
Though it needs to be conﬁrmed by re-analysis of
the original investigators data, and results from an
older patient population may be more skewed than
those from those in young and healthy men, for
example the approximately 10% increase in upper
and lower limits seen in one such study [9], it may be
possible to estimate more appropriate ‘reference
ranges’ from the ﬁgures given in the existing
literature.
The clinical importance of these two key factors,
analytical variation and the log transformation of data
used in establishing ‘reference ranges’, is clearly
demonstrated by this recent study [9]. Using a
reference panel of sera from healthy eugonadal young
men with veriﬁed normal reproductive function,
major differences were found to exist between
commercial TT immunoassays, as well as divergence
from the GC/MS standard. The authors concluded
‘This impairs their clinical diagnostic utility and
requires substantial improvements in automated T
immunoassay technologies or a switch to GC/MS
methods’.
As an example of the direct clinical relevance of
these factors, when combined with differences in
mathematical calculations of the lower end of
reference ranges, this study appeared to totally
invalidate the criteria for Australian men to qualify
for testosterone treatment under the Pharmaceutical
Beneﬁt System (PBS) [40], which sets a limit of
8 nmol/L, (230 ng/dl) for the diagnosis of ‘hypogo-
nadism’ (Figure 2).
These ﬁgures suggest that the majority of men
falling within 4 nmol/L (115 ng/dl) of the PBS range
would fail to qualify for testosterone treatment under
the present regulations.
The frequently urged solutions to switch to mass
spectrometry-based methods, or for each laboratory
to establish its own reference range from a large pool
of healthy, reproductively normal young men, is
seldom practical outside research centres, and it is
clinically undesirable to have local variations in
methodology affecting the interpretation of key
endocrine results.
Ethnic differences
It has recently become apparent that genetic differ-
ences can affect the level of androgens, and SHBG in
different races, requiring different interpretation of
these ﬁgures in relation to ethnic mix. A study in
Manchester [41] showed that mean TT levels in
Figure 1. Changes in means and 2 SD ‘reference ranges’ for total
testosterone levels at different ages according to the ﬁgures of
Vermeulen [39] for 249 healthy men, comparing ﬁgures calculated
from arithmetic and logarithmic distributions [6].
Figure 2. Lower Limits of TT in relation to PBS ‘cut-off limit’
based on results from 7 different ‘leading Australian laboratories’
(A-G) using various fully automated methods for measuring TT
[9] compared to the GC/MS standard reference method. The lines
connect the limits in each lab derived from arithmetic and
logarithmic calculations, compared to the manufacturers quoted
reference range.
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23% lower than those of African-Caribbean origin.
The corresponding means for FT were 24% and
25% lower.
Racial, familial and individual variations in the
androgen receptor can affect the level of both
androgens and gonadotrophins, as well as organ-
speciﬁc sensitivity or resistance to their actions, and
therefore the resulting symptoms and signs of
androgen deﬁciency [42–44].
Choice of androgen measures in the diagnosis
of androgen deﬁciency
As can be seen from the above discussion, there is no
perfect measure of androgen activity, though some
appear more useful than others.
Total testosterone (TT)
Though unfortunately TT is the most commonly
measured and quoted, it is a poor indicator of clinical
androgen activity, falling least with age, and having
the weakest relationship with most clinical states and
their response to testosterone treatment.
These factors underline the view of Atkinson et al.
[45] that ‘Because of the variability in serum testoster-
one concentration in the normal male during the day,
from person to person, and among assays, there is no
accepted testosterone value used as a cut-off to deﬁne
testosterone deﬁciency. Symptoms, etiology, clinical
impression, and a very low or low-normal testosterone
aid the diagnosis of hypogonadism’.
Free androgen index (FAI)
This has the merit of being easy to calculate, and
makes some allowance for the important effect of
SHBG. It has however been attacked on theoretical
grounds by Kapoor et al. [46] when used in men, on
the basis that the binding capacity of SHBG needs to
greatly exceed the concentration of its ligand
testosterone for the equation to be valid. Vermeulen
et al. have also shown it to correlate poorly with FT
results obtained by equilibrium dialysis [47].
Bioavailable testosterone (BT)
Also known as ‘free and weakly-bound’ testosterone,
this has the advantage that the ammonium sulphate
precipitation is simple, cheap and direct, and has
been recommended for screening for androgen
deﬁciency [48].
Though popular in America and Canada, it is
however seldom measured in Europe, and obscures
the information gained by measuring SHBG. There
is also the question of whether the testosterone,
weakly bound to albumin, is actually free and
biologically active in its short transit through the
capillaries in all parts of the body, e.g. the brain. The
albumin-bound fraction is also considerably greater,
but less variable, than the free fraction, and variations
in the former may mask smaller but potentially more
important changes in the latter, which is usually only
5–10% of the Bio-T.
Calculated free testosterone (CFT)
As it has been found that CFT and FT measured by
equilibrium dialysis [47] show a higher correlation
than any of the other measures, it was concluded that
‘calculated FT is a reliable index of FT, that
calculated non-speciﬁcally bound T reﬂects non-
SHBG-T, and that immuno-assayable SHBG is a
reliable measure of SHBG binding sites’. These key
statements from this detailed study must be regarded
as the deﬁnitive ideas at present in this complex ﬁeld,
and make CFT the laboratory measure of choice. A
nomogram for deriving CFT from total testosterone
and SHBG, using the equation provided by Vermeu-
len et al. [47], has recently become available [6].
Salivary testosterone (ST)
In research studies where frequent sampling is
required, especially biosocial and population studies
to detect androgen deﬁcient states, salivary testoster-
ones are potentially very useful. However, they
require careful collection and preservation in special
plastic sampling devices under standardized condi-
tions, without blood contamination, and the use of
suitably sensitive assay methods to avoid ‘The
trouble with salivary testosterone’ [49].
Goncharov et al. showed they are stable for up to
ﬁve days at room temperature, enabling samples to
be transported by post, and for up to six months at
7208C [50]. Development of ultrasensitive lumines-
cent assays, which the authors recommend as being
more sensitive and therefore preferable to radio-
immunoassay methods for this purpose, has made it
possible to measure the testosterone in the saliva of
normal and androgen deﬁcient men, with a mean
precision of 3.5%, 4.7% and 7.8% for intra-assay,
inter-asssay and between-lot variation. This study
also showed that morning ST levels correlated well
with CFT in both groups.
Another study looking at age-related change in
salivary testosterone among Japanese males used a
radioimmunoassay kit modiﬁed for saliva [51]. There
was a signiﬁcant decrease in salivary testosterone
values from 20s to 40s and older but no further
decline after 40 through 90 years old. These results
suggest that neither a constant decrease of salivary
testosterone values or markedly reduced intraindivi-
dual ﬂuctuations are universal aspects of aging. Older
males may maintain relatively high testosterone levels
compared to younger men and a relatively ‘robust’
neuroendocrinological system. The ﬁndings may
however be related to the low levels of obesity, and
exceptional longevity of Japanese males [52].
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Morley et al. [53] who looked at salivary testosterone
in 1,454 American men between the ages of 20 to 89
years and showed a 47% decline across that age
range. They also showed that salivary testosterone
was highly correlated with BT, CFT and TT. The
ST levels related signiﬁcantly to symptoms of
androgen deﬁciency on both the Saint Louis
University ADAM questionnaire and the Aging Male
Symptom scale. However, it was concluded that
‘Salivary testosterone is not a better assay than other
measures to diagnose hypogonadism’.
Conclusions
Many of the factors discussed in relation to the
validity of catecholamine assays [54] nearly 40 years
ago seem equally applicable to the current state of
androgen measurement and interpretation, but have
potentially more serious clinical consequences.
There appear to be so many confounding variables
in obtaining, preserving and analysing androgen
samples (Table I) that conventional interpretation
in relation to arbitrary reference ranges seems
inappropriate. It is suggested that in men, laboratory
assays can support, but not always exclude, a
diagnosis of androgen deﬁciency. A typical symp-
toms as assessed by a complete physical examination
and fully validated questionnaires such as the Aging
Male Symptom Scale [36] may in cases of doubt
indicate a therapeutic trial of testosterone treatment
in patients without contraindications.
In women and children, unless GC/MS is used,
methodological inaccuracies alone can invalidate
testosterone measurements using the commonly
available direct immuno-assays.
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